Tuesday August 12 8:03 AM EDT
Company Press Release
ImmuDyne Inc. Appoints New Chairman and Director and Announces Resignation of President
HOUSTON--(BW HealthWire)--Aug. 12, 1997--ImmuDyne, Inc.(IMMD), announced today changes in its board of directors and executive officers.
Robert Nakamura, M.D., a director of the company, will become the chairman of the board of directors, replacing James D. Wood. Wood will continue as a director of the company and will hold the honorary title of chairman emeritus of the company. The company also announced that John Joshua will replace Andrew P. Calhoun as a director of the company. Calhoun, who joined the board approximately three months ago at the request of L. Melvin Cooper, is resigning for personal reasons and not as a result of any dispute or disagreement with the company or its management.
Dr. Nakamura is the chairman emeritus and senior consultant with the Department of Pathology at Scripps Clinic and Research Foundation. He is a renowned expert and author in the fields of pathology and immunology.
Joshua is currently the chief financial officer of McLaughlin International Inc., a marketing firm based in San Antonio, Texas. From 1992-1995, Joshua was president and CEO of Excel Service Corp., where his company specialized in management services to airports throughout the United States. From 1988-1992, Joshua was chief financial officer for Delta Food Service which was one of the top 50 minority owned companies in the United States.
Joshua is a graduate of the University of Alabama at Birmingham and is a member in numerous professional and civic organizations. Joshua's appointment to the board of directors is at the request of Mark McLaughlin and fulfills the obligations of the company in connection with the agreed summary judgment between the company and McLaughlin in
connection with litigation in San Antonio, Texas. See earlier press releases of the company regarding such litigation.
The company also announced that Cooper, its president, has resigned effective August 13, 1997, to pursue other opportunities. Dr. Leonid Ber has been appointed by the company as chief operating officer and will assume responsibility for the operational aspects of the company. Dr. Ber has been with ImmuDyne for three years, serving the most recent two as vice president of Research & Development with an emphasis in immune technology applications in human nutrition and skin care. Dr. Ber formerly practiced and taught medicine at Komi Republical Hospital, Russia where his specialization was hematology and immunology. Dr. Ber will also assume the remaining duties of president until a successor for Cooper is appointed by the board of directors of the company.
ImmuDyne Inc. is traded on the NASD Automated Bulletin Board under the symbol IMMD. ImmuDyne Inc. is a Texas based company specializing in macrophage technology and immune system stimulants for cosmetic, human nutritional and aquacultural use. For investment information, contact Denise Sadberry, 713/783-7034. |
